Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2022
Price :
$35
*
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Acronyms KODIAC-04
- Sponsors AstraZeneca
- 26 Oct 2022 Results of pooled analysis from KODIAC 4/5; NCT01309841/NCT01323790 studies, (n=1337) assessing the efficacy of naloxegol in providing clinically meaningful HR-QOL improvement utilizing the patient assessment of constipation quality of life questionnaire (PAC-QOL) in patients with opioid-induced constipation, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022.
- 26 Oct 2022 Results of a pooled analysis assessing symptom improvement utilizing patient assessment of constipation symptoms questionnaire (PAC-SYM) from two randomized, placebo-controlled trials (KODIAC-04 and KODIAC-05) presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
- 27 Oct 2021 Results from pooled analysis of two trials (KODIAC 4 and 5) assessing initial onset and maintenance of response in subjects with extreme OIC at baseline presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021